Twin Focus Capital Partners’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Twin Focus Capital Partners’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-675	Closed	-$71K	–	110
2018 Q1	$71K	Hold	675	–	–	0.04%	102
2017 Q4	$86K	Hold	675	–	–	0.04%	96
2017 Q3	$78K	Hold	675	–	–	0.04%	98
2017 Q2	$88K	Hold	675	–	–	0.05%	97
2017 Q1	$111K	Hold	675	–	–	0.07%	91
2016 Q4	$63K	Hold	675	–	–	0.04%	86
2016 Q3	$69K	Hold	675	–	–	0.05%	85
2016 Q2	$80K	Sell	675 -624	-48%	-$62.5K	0.06%	79
2016 Q1	$91K	Buy	1,299 +380	+41%	+$25.1K	0.09%	72
2015 Q4	$67K	Buy	919 +367	+66%	+$28.1K	0.07%	88
2015 Q3	$44K	Hold	552	–	–	0.06%	83
2015 Q2	$43K	Hold	552	–	–	0.05%	91
2015 Q1	$43K	Buy	+552	New	+$49.2K	0.03%	94

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

Twin Focus Capital Partners's VBIV Position: Q2 2018 in Review

Twin Focus Capital Partners sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2018, closing a stake of 675 shares — an estimated $71K sold.

Twin Focus Capital Partners first reported a position in VBIV in Q1 2015 and held it in 13 quarters. The position peaked at $111K in Q1 2017. 48 funds tracked by Wall St. Rank hold VBIV as of Q2 2018.

Twin Focus Capital Partners reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2018 after selling out during the quarter.
Twin Focus Capital Partners sold 675 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2018, an estimated $71K.
Twin Focus Capital Partners first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2015 and held it in 13 quarters.
Twin Focus Capital Partners's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $111K in Q1 2017.
48 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2018.

Based on Twin Focus Capital Partners's 13F filing for Q2 2018, filed 10 Aug 2018.